Advertisement U-Systems to initiate breast cancer screening study - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

U-Systems to initiate breast cancer screening study

U-Systems, a developer and marketer of breast ultrasound systems, has announced its plans to conduct a multi-center breast cancer screening study named somoInSIGHT, with more than 20,000 women, using its proprietary automated breast ultrasound system.

The clinical study will evaluate the sensitivity and specificity of X-ray mammography (XRM) and automated breast ultrasound system (ABUS) together, as compared to XRM alone, as a breast cancer screening method in women with greater than 50% parenchymal density.

Bob Foley, U-System’s vice president of clinical affairs, said: “We are initiating this multi-center study with our somov to address that population of women with dense breasts. This is an undertaking that U-Systems feels is vital in the battle to find cancers earlier and at a more curable stage.

“We believe that the somoInSIGHT study will demonstrate that screening dense breasted patients with ABUS and XRM is more beneficial than XRM alone.”